AJP - Heart Watch the video to learn how APS reaches out to developing nations.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Heart Circ Physiol 295: H220-H226, 2008. First published May 16, 2008; doi:10.1152/ajpheart.00289.2008
0363-6135/08 $8.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental Materials
Right arrow All Versions of this Article:
295/1/H220    most recent
00289.2008v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Koyanagi, T.
Right arrow Articles by Mochly-Rosen, D.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Koyanagi, T.
Right arrow Articles by Mochly-Rosen, D.

Alteration of gene expression during progression of hypertension-induced cardiac dysfunction in rats

Tomoyoshi Koyanagi,1 Lily Y. Wong,2 Koichi Inagaki,1 Olga V. Petrauskene,2 and Daria Mochly-Rosen1

1Department of Chemical and Systems Biology, Stanford University School of Medicine, Stanford; and 2Applied Biosystems, Foster City, California

Submitted 17 March 2008 ; accepted in final form 10 May 2008

Hypertension induced by high-salt diet in Dahl salt-sensitive rats leads to compensatory cardiac hypertrophy by ~11 wk, cardiac dysfunction at ~17 wk, and death from cardiac dysfunction at ~21 wk. It is unclear what molecular hallmarks distinguish the compensatory hypertrophy from the decompensated cardiac dysfunction phase. Here we compared the gene expression in rat cardiac tissue from the compensatory hypertrophic phase (11 wk, n = 6) with the cardiac dysfunction phase (17 wk, n = 6) and with age-matched normotensive controls. Messenger RNA levels of 93 genes, selected based on predicted association with cardiac dysfunction, were measured by quantitative real-time PCR. In the hypertrophic phase, the expression of three genes, atrial natriuretic peptide (ANP; P = 0.0089), brain natriuretic peptide (P = 0.0012), and endothelin-1 precursor (P = 0.028), significantly increased, whereas there was decreased expression of 24 other genes including SOD2 (P = 0.0148), sarco(endo)plasmic reticulum Ca2+-ATPase 2a (P = 0.0002), and ryanodine receptor 2 (P = 0.0319). In the subsequent heart cardiac dysfunction phase, the expression of an additional 20 genes including inducible nitric oxide synthase (NOS; P = 0.0135), angiotensin I-converting enzyme (P = 0.0082), and IL-1β (P < 0.0001) increased, whereas the expression of seven genes decreased compared with those of age-matched controls. Furthermore, the expression of 22 genes, including prepro-endothelin-1, ANP, angiotensin I-converting enzyme, β1-adrenergic receptor, SOD2, and endothelial NOS, significantly changed in the cardiac dysfunction phase compared with the compensatory hypertrophic phase. Finally, principal component analysis successfully segregated animals with decompensatory cardiac dysfunction from controls, as well as from animals at the compensated hypertrophy phase, suggesting that we have identified molecular markers for each stage of the disease.

quantitative polymerase chain reaction; diagnosis; heart failure; left ventricular



Address for reprint requests and other correspondence: D. Mochly-Rosen, Dept. of Chemical and Systems Biology, Stanford Univ. School of Medicine, CCSR, Rm. 3145A, 269 Campus Dr., Stanford, CA 94305-5174 (e-mail: mochly{at}stanford.edu)







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2008 by the American Physiological Society.